307 related articles for article (PubMed ID: 16151390)
1. Flexibility--the guiding principle for antibody manufacturing.
Carson KL
Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
[TBL] [Abstract][Full Text] [Related]
2. Formulation and manufacturability of biologics.
Shire SJ
Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
[TBL] [Abstract][Full Text] [Related]
3. Biopharmaceuticals in China.
Hu X; Ma Q; Zhang S
Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic antibodies market to 2008.
Pavlou AK; Belsey MJ
Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing of biopharmaceuticals and implications for biosimilars.
Wurm FM
Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
[No Abstract] [Full Text] [Related]
6. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
7. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
8. Upping the ante on antibodies.
Baker M
Nat Biotechnol; 2005 Sep; 23(9):1065-72. PubMed ID: 16151393
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
Närhi M; Nordström K
Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
[TBL] [Abstract][Full Text] [Related]
10. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
[TBL] [Abstract][Full Text] [Related]
11. Aggregates in monoclonal antibody manufacturing processes.
Vázquez-Rey M; Lang DA
Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
[TBL] [Abstract][Full Text] [Related]
12. New opportunities for biocatalysis: making pharmaceutical processes greener.
Woodley JM
Trends Biotechnol; 2008 Jun; 26(6):321-7. PubMed ID: 18436317
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical proteins: opportunities and challenges.
Birch JR; Onakunle Y
Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
[No Abstract] [Full Text] [Related]
14. Biotech pharmaceuticals and biotherapy: an overview.
Steinberg FM; Raso J
J Pharm Pharm Sci; 1998; 1(2):48-59. PubMed ID: 10945918
[TBL] [Abstract][Full Text] [Related]
15. Building biomanufacturing capacity--the chapter and verse.
Kamarck ME
Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
[TBL] [Abstract][Full Text] [Related]
16. Specifications from a biotechnology industry perspective.
Garnick RL
Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
[TBL] [Abstract][Full Text] [Related]
17. The farmyard drug store.
Nature; 2006 Sep; 443(7107):16-7. PubMed ID: 16957702
[No Abstract] [Full Text] [Related]
18. Discovery and development of biopharmaceuticals: current issues.
Strohl WR; Knight DM
Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
[No Abstract] [Full Text] [Related]
19. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
Gikanga B; Chen Y; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
[TBL] [Abstract][Full Text] [Related]
20. New pharma-biotech company formation in India.
Saberwal G
Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
